Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,042 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,672 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03689582 | Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer | terminated | Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01018563 | An Open Label Extension Study of the Efficacy of MORAb-003 | terminated | Phase 2 | 3 | MorphotekINDUSTRY | 2 | Dec 8, 2021 | clinicaltrials |
| NCT02648919 |
| Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer |
| terminated |
| Phase 2 |
| 6 |
| University of HawaiiOTHER |
| 1 |
| Nov 26, 2021 |
| clinicaltrials |
| NCT02506114 | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | terminated | Phase 2 | 15 | Lawrence FongOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT01312389 | A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 3 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 15, 2021 | clinicaltrials |
| NCT03342417 | Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients | terminated | Phase 2 | 5 | ExcellaBio LLCINDUSTRY | 1 | Nov 9, 2021 | clinicaltrials |
| NCT00900562 | Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy | terminated | Phase 2 | 19 | PharmaMarINDUSTRY | 1 | Oct 28, 2021 | clinicaltrials |
| NCT01035658 | Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma | terminated | Phase 1 / Phase 2 | 22 | SCRI Development Innovations, LLCOTHER | 1 | Oct 28, 2021 | clinicaltrials |
| NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02508636 | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer | terminated | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT01805037 | Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas | terminated | Phase 1 / Phase 2 | 20 | Northwestern UniversityOTHER | 1 | Sep 1, 2021 | clinicaltrials |
| NCT03545165 | 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | terminated | Phase 1 / Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | terminated | Phase 2 | 2 | Seattle Institute for Biomedical and Clinical ResearchOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | terminated | Phase 2 | 21 | University of OklahomaOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT02805894 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | terminated | Phase 1 / Phase 2 | 5 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT03029585 | Phase II Study of Intraperitoneal NanoPac® in Patients With Ovarian Cancer | terminated | Phase 2 | 10 | NanOlogy, LLCINDUSTRY | 1 | Apr 27, 2021 | clinicaltrials |
| NCT03937791 | Immunotherapy With E7 T Cell Receptor T Cells for Vulvar High-Grade Squamous Intraepithelial Lesions | terminated | Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Apr 13, 2021 | clinicaltrials |
| NCT02685267 | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer(Doce/Enza) | terminated | Phase 2 | 9 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | terminated | Phase 2 | 71 | EndocyteINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | terminated | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT01334047 | Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients | terminated | Phase 1 / Phase 2 | 5 | Steinar AamdalOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT03146663 | NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer | terminated | Phase 2 | 53 | NuCana plcOTHER | 2 | Feb 21, 2021 | clinicaltrials |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | terminated | Phase 2 | 1 | Donald Trump, MDOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03622931 | Patients With Relapsed Ovarian Cancer (2nd and 3rd Line) Treated With Chemotherapy According to AGO Guidelines(TRACEII) | terminated | Phase 2 | 21 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT00285415 | A Phase II Evaluation of Docetaxel and Carboplatin Followed by Tumor Volume Directed Pelvic Irradiation | terminated | Phase 2 | 46 | Carilion ClinicOTHER | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT00757757 | A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | terminated | Phase 1 / Phase 2 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00780975 | A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer | terminated | Phase 2 | 8 | PharmaMarINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT00506779 | Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma | terminated | Phase 1 / Phase 2 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 18, 2020 | clinicaltrials |
| NCT01511055 | Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand | terminated | Phase 2 | 27 | Mayo ClinicOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT03312114 | Anti-PD-L1 and SAbR for Ovarian Cancer | terminated | Phase 2 | 5 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 12, 2020 | clinicaltrials |
| NCT00503581 | Megestrol in Treating Patients With Endometrial Neoplasia or Endometrial Hyperplasia | terminated | Phase 2 | 9 | Gynecologic Oncology GroupNETWORK | 1 | Nov 3, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01928485 | Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer | terminated | Phase 2 | 6 | Sanjay Gupta PhDOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00004026 | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy | terminated | Phase 2 | 80 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT01690468 | PTX-200 and Carboplatin in Ovarian Cancer | terminated | Phase 1 / Phase 2 | 15 | Prescient Therapeutics, Ltd.INDUSTRY | 1 | Sep 24, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT01535157 | Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer | terminated | Phase 1 / Phase 2 | 12 | South Plains Oncology ConsortiumNETWORK | 1 | Aug 27, 2020 | clinicaltrials |
| NCT02045433 | Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer | terminated | Phase 2 | 16 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT02326844 | BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03587129 | Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer | terminated | Phase 2 | 1 | First Affiliated Hospital of Harbin Medical UniversityOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT01545882 | A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer(OTT10-06) | terminated | Phase 2 | 5 | Ottawa Hospital Research InstituteOTHER | 1 | May 7, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Jan 5, 2022source: clinicaltrials